Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis
CHIC
1 other identifier
interventional
450
1 country
19
Brief Summary
The purpose of this study is to evaluate 3 imaging techniques and their associations : MRI, CTscanner and enhanced contrast ultrasound for the diagnosis of small (\< 3 cm) hepatocellular carcinoma for patients with cirrhosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable hepatocellular-carcinoma
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 20, 2009
CompletedFirst Posted
Study publicly available on registry
February 23, 2009
CompletedStudy Start
First participant enrolled
March 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedFebruary 4, 2010
February 1, 2009
1 year
February 20, 2009
February 3, 2010
Conditions
Outcome Measures
Primary Outcomes (1)
Report of proportion of the positives truths and the positive wrong for an examination
one year
Interventions
all patients have : MRI, CTscanner, enhanced contrast ultrasound
Eligibility Criteria
You may qualify if:
- age \> 18 hears
- presence of one or several nodules \< 3 cm
- known or suspected cirrhosis
You may not qualify if:
- psychiatric disease
- contraindication to one of the 3 imaging examinations (CTscanner, MRI, enhanced contrast ultrasound
- patient already treated by chemoembolization
- recurrence on the coagulation zone of a nodule already treated by per-cutaneous tumour destruction
- presence of a tumour (\> 3 cm) associated to the nodule
- pregnant woman or breast-feeding woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (19)
CHU Angers
Angers, France
Hôpital Saint-André
Bordeaux, 33300, France
Chu
Caen, 14033, France
hôpital Beaujon
Clichy, 92110, France
hôpital Henri Mondor
Créteil, 94010, France
Hôpital Du Bocage
Dijon, 21079, France
CHU
Grenoble, 38043, France
Hôpital de la croix rousse
Lyon, 69317, France
Hôpital E. Herriot
Lyon, 69437, France
Hôpital Saint Éloi
Montpellier, 34295, France
Hôpital Brabois
Nancy, 54500, France
Hôpital Hôtel Dieu
Nantes, 44093, France
hôpital archet II
Nice, 06003, France
Hôpital Saint Antoine
Paris, 75012, France
Hôpital Haut-Lévèque
Pessac, 33604, France
Hôpital Pontchaillou
Rennes, 35033, France
Hôpital Nord
Saint-Etienne, 42055, France
Hôpital Paul Brousse
Villejuif, 94804, France
Institut Gustave Roussy
Villejuif, 94805, France
Related Publications (2)
Paisant A, Vilgrain V, Riou J, Oberti F, Sutter O, Laurent V, Rodes A, Guiu B, Cassinotto C, Trillaud H, Bricault I, Michalak S, Bruno O, Ronot M, Aube C. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. J Hepatol. 2020 May;72(5):937-945. doi: 10.1016/j.jhep.2019.12.011. Epub 2019 Dec 21.
PMID: 31870951DERIVEDAube C, Oberti F, Lonjon J, Pageaux G, Seror O, N'Kontchou G, Rode A, Radenne S, Cassinotto C, Vergniol J, Bricault I, Leroy V, Ronot M, Castera L, Michalak S, Esvan M, Vilgrain V; CHIC Group. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017 Oct;37(10):1515-1525. doi: 10.1111/liv.13429. Epub 2017 Apr 26.
PMID: 28346737DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
February 20, 2009
First Posted
February 23, 2009
Study Start
March 1, 2009
Primary Completion
March 1, 2010
Last Updated
February 4, 2010
Record last verified: 2009-02